Compare Gold Fields Limited (GFI) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Philip Morris International Inc. — how do they compare? Gold Fields Limited trades at $40.97 (market cap $36.72B), while Philip Morris International Inc. trades at $186.4 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 7.9× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (5.64%). Which is the better fit depends on your goals.
| GFI | PM | |
|---|---|---|
Market Cap | $36.72B | $289.90B |
Sector | Basic Materials | Consumer Staples |
52-Week High | $61.52 | $200.17 |
52-Week Low | $29.31 | $144.33 |
Enterprise Value | $38.16B | $333.02B |
Dividend Yield | 5.64% | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $40.82, up 9.32% in 24 hours, reflecting strong momentum near recent highs. The stock shows a bullish technical signal with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Fundamentally, GFI exhibits robust profitability with a 40.76% net income margin and attractive valuation metrics, including a P/E of 10.36. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses, while 2025 revenue is projected to surge to $8.8B. Institutional interest is evident with Allspring Global increasing its stake by 62.3% in Q1 2026 (SEC filing, 2026-07-18).
The outlook for GFI is positive, driven by strong gold prices and operational growth, with a consensus price target of $52.00 offering ~27% upside. Risks include cost inflation, geopolitical factors affecting mining operations, and volatile cash flows from heavy investing activities. Analyst sentiment is cautiously optimistic with 44% buy ratings, but investors should monitor execution on earnings targets and debt levels, which rose to 25.01% of assets in 2024.
Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.
PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
